Get started
Author

Joanna Brzezinska

Observed names: J. Brzezińska, Joanna Brzezińska
ORCID: 0000-0001-5807-9928
Observed ORCID: 0000-0001-5807-9928
OpenAlex ID: A5007885100
Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors
2020 · Roman Blaszczyk, Joanna Brzezinska, et al. · ACS Medicinal Chemistry Letters · 46
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · Molecular Cancer Therapeutics · 44
PDF
OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer
2022 · Marcin Mikołaj Grzybowski, Paulina Seweryna Stańczak, et al. · Cancers · 44
PDF
Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion
2023 · Anna Gzik, Bartlomiej Borek, et al. · European Journal of Medicinal Chemistry · 13
Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors
2017 · M.M. Grzybowski, P.S. Stańczak, et al. · Annals of Oncology · 11
Targeting ARG2 as a novel therapeutic approach for cancer
2019 · M.M. Grzybowski, J. Pęczkowicz-Szyszka, et al. · Annals of Oncology · 6
Structure-Guided Discovery of OAT-4828 as Potent, Selective, and Orally Bioavailable USP7 Inhibitor with In Vivo Antileukemic Activity
2026 · Jacek Chrzanowski, Julita Nowicka, et al. · Journal of Medicinal Chemistry · 2
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · 2
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Works count: 66
Citation count: 168
H-index: 6
I10-index: 5
Year
Topic
Type